Gene · 7516
Papers1,770
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
101 to 120 of 1,770
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Clinicopathological and molecular analysis of microsatellite instability in prostate cancer: a multi-institutional study in China. | Front Oncol | 2023 | 37901334 | PubTator, text mining | PubMed |
| DNA Double-Strand Break Response and Repair Gene Polymorphisms May Influence Therapy Results and Prognosis in Head and Neck Cancer Patients. | Cancers (Basel) | 2023 | 37894339 | PubTator, text mining | PubMed |
| FIGNL1 AAA+ ATPase remodels RAD51 and DMC1 filaments in pre-meiotic DNA replication and meiotic recombination. | Nat Commun | 2023 | 37891173 | PubTator, text mining | PubMed |
| DNA Double-Strand Break Repair Inhibitors: YU238259, A12B4C3 and DDRI-18 Overcome the Cisplatin Resistance in Human Ovarian Cancer Cells, but Not under Hypoxia Conditions. | Curr Issues Mol Biol | 2023 | 37886943 | PubTator, text mining | PubMed |
| Genetic predictors of neurocognitive outcomes in survivors of pediatric brain tumors. | J Neurooncol | 2023 | 37878192 | PubTator, text mining | PubMed |
| Exploring homologous recombination repair and base excision repair pathway genes for possible diagnostic markers in hematologic malignancies. | Mol Genet Genomics | 2023 | 37861816 | PubTator, text mining | PubMed |
| Similarities and differences in gene expression profiles of BRCA1 methylated and mutated epithelial ovarian cancers. | Front Oncol | 2023 | 37854675 | PubTator, text mining | PubMed |
| RAD51 paralogs synergize with RAD51 to protect reversed forks from cellular nucleases. | Nucleic Acids Res | 2023 | 37843130 | PubTator, text mining | PubMed |
| p53 in the Molecular Circuitry of Bone Marrow Failure Syndromes. | Int J Mol Sci | 2023 | 37834388 | PubTator, text mining | PubMed |
| [BRCA-like breast cancer patients benefit from cisplatin plus veliparib-results from the S1416 phase II study]. | Strahlenther Onkol | 2023 | 37823898 | PubTator, text mining | PubMed |
| RAD51 is a poor prognostic marker and a potential therapeutic target for oral squamous cell carcinoma. | Cancer Cell Int | 2023 | 37798649 | PubTator, text mining | PubMed |
| Evaluating the prevalence of inborn errors of immunity in adults with chronic immune thrombocytopenia or Evans syndrome. | Blood Adv | 2023 | 37792884 | PubTator, text mining | PubMed |
| Tumorigenic effects of human mesenchymal stromal cells and fibroblasts on bladder cancer cells. | Front Oncol | 2023 | 37781195 | PubTator, text mining | PubMed |
| Impact of Interaction between Single Nucleotide Polymorphism of XRCC1, XRCC2, XRCC3 with Tumor Suppressor Tp53 Gene Increases Risk of Breast Cancer: A Hospital Based Case-Control Study. | Asian Pac J Cancer Prev | 2023 | 37774058 | PubTator, text mining | PubMed |
| Single Nucleotide Polymorphisms in DNA Repair Genes (XRCC1, XRCC2, XRCC3) and Their Association with Radiotherapy Toxicity among Head and Neck Cancer Patients:A Study from South-Western Maharashtra. | Asian Pac J Cancer Prev | 2023 | 37774056 | PubTator, text mining | PubMed |
| Class I HDAC Inhibition Leads to a Downregulation of FANCD2 and RAD51, and the Eradication of Glioblastoma Cells. | J Pers Med | 2023 | 37763083 | PubTator, text mining | PubMed |
| Evaluating the Utility of ctDNA in Detecting Residual Cancer and Predicting Recurrence in Patients with Serous Ovarian Cancer. | Int J Mol Sci | 2023 | 37762691 | PubTator, text mining | PubMed |
| Unraveling MYC's Role in Orchestrating Tumor Intrinsic and Tumor Microenvironment Interactions Driving Tumorigenesis and Drug Resistance. | Pathophysiology | 2023 | 37755397 | PubTator, text mining | PubMed |
| Dose-Dependent Shift in Relative Contribution of Homologous Recombination to DNA Repair after Low-LET Ionizing Radiation Exposure: Empirical Evidence and Numerical Simulation. | Curr Issues Mol Biol | 2023 | 37754249 | PubTator, text mining | PubMed |
| Germline Sequencing Analysis to Inform Clinical Gene Panel Testing for Aggressive Prostate Cancer. | JAMA Oncol | 2023 | 37733366 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/7516/papers?page=6